The first clinical trials of LSD1 inhibition in AML were initiated with the use of tranylcypromine (TCP), which has long been in clinical use as a MAO inhibitor for the treatment of depression; see Table 3. This evidence concerns the gene KDM1A and acute myeloid leukemia.